PR Newswire updates

10.5
2026
The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
10.5
2026
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
10.5
2026
ICAC and UNODC jointly debut the pioneering Prison Guide, ICAC Commissioner: charting the way for enhancing global prison integrity

Petal Ads Hosts "Think Tank 2025" Seminar in Japan to Empower Japanese Companies' Global Expansion
April 26, 2025
Asia's Premier Poker Festival JOPT 2025 Grand Final: 12 Days of Pure Poker Excitement in Tokyo
April 26, 2025
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
April 26, 2025
51Talk Online Education Group Files Annual Report on Form 20-F for Fiscal Year of 2024
April 26, 2025
Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
April 26, 2025
Concord Medical Files Annual Report on Form 20-F for Fiscal 2024
April 26, 2025
Zepp Health Corporation Files 2024 Annual Report on Form 20-F
April 26, 2025
Amcor to report fiscal 2025 third quarter results
April 26, 2025

The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth

The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth

Global anniversary campaign marks the first step of the brand’s transformation…

Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers

Published multicenter study found higher complete wound closure rates and faster…

ICAC and UNODC jointly debut the pioneering Prison Guide, ICAC Commissioner: charting the way for enhancing global prison integrity

ABU DHABI, UAE and HONG KONG, Oct. 5, 2026 /PRNewswire/ — ICAC Commissioner…

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

The only known investigational therapy for SBMA in Phase 3 development worldwide…